ClinicalTrials.gg
WithdrawnNCT05196373Updated Jul 29, 2026

Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars

A Phase 1/2 interventional study of STP705 in Hypertrophic Scar, sponsored by Sirnaomics. Withdrawn at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Sirnaomics · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Study was cancelled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Adult patients with hypertrophic scars 30 Subjects in Dose Escalation 20 Subjects in Dose Expansion Intrascar injection of STP705 weekly for 4 weeks

Read the detailed description

An open label study design to evaluate the preliminary efficacy of STP705 in adult patients with hypertrophic scars.

The study is divided into 2 stages:

1. Dose Escalation: 30 subjects to be enrolled in this stage with a total of 6 dose groups.

3 subjects will be enrolled in 10ug and 20ug groups and 6 subjects in the subsequent groups of 40ug, 60ug, 80u and 100ug.

2. Dose Expansion:1-2 dose groups will be selected and 20 subjects will be enrolled in each group.

02

Conditions studied

  • Hypertrophic Scar
03

In context

Cicatrix, Hypertrophic

129 studies on the registry are indexed under Cicatrix, Hypertrophic; 31 are open to participants now.

Browse Cicatrix, Hypertrophic studies →

Lead sponsor

Sirnaomics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 and ≤ 45 years old at the time of signing the ICF,
  2. Diagnosed with hypertrophic scars, with all the following characteristics:

    1. Linear hypertrophic scar, with a width of 0.3-1.0 cm and a length of ≥10 cm;
    2. Scars with any of the following characteristics: redness or purpleness, stiffness, rough surface, significant swelling, visible dilated capillaries on the surface, and possibly accompanied by pain or itching;
    3. The course of the disease is 6 to 24 months (inclusive);
    4. Scars are not located on the face, front of the neck, feet, hands, knees, elbows or any joints;
  3. The examination during the screening period must meet the following criteria: medical history, physical examination (excluding hypertrophic scar), 12-lead , vital signs, laboratory examinations are judged by the investigator to meet the requirements, and no abnormalities were observed;
  4. Subjects of (male or female) must take effective medical measures during the study and within 6 months after the end of administration;
  5. Subjects voluntarily participate in this clinical trial and sign the ICF, can understand and comply with the study procedures, and complete the entire study as specified by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with keloid or burn scar;
  2. Positive in surface antigen, antibody, (HIV), or syphilis antibody tests;
  3. Medication history of use (including inhaled steroids, triamcinolone acetonide, etc.) and COX-2 inhibitors within 3 months before the first injection of the study (if 5 times the half-life is longer than 3 months, then 5 times the half-life will prevail);
  4. Impaired immune function (such as cancer, or other diseases that affect the basic immune responses);
  5. Concomitant diseases that is uncontrolled or poorly controlled or may affect the study, including cardiovascular, lung, kidney, endocrine, liver, nerve, mental, immune, gastrointestinal, blood, urogenital, skeletal or metabolic disorders at the investigator's discretion;
  6. Known to be allergic to STP705 or any components of its prescription;
  7. Having difficulty in venous blood collection, or having a history of needle fainting or blood fainting;
  8. Infection or trauma in the site to be treated;
  9. Pregnant and lactating women;
  10. Participated in other clinical studies and received treatment within 3 months before the first injection;
  11. Blood donation or blood loss ≥400 mL within 3 months before the first injection (except for female blood loss during menstrual period), or planning to donate blood or blood components during the study period or within 3 months after the end of the study;
  12. History of drug abuse/dependence or drug history or positive in drug abuse screening (screening items can include: morphine, tetrahydrocannabinol acid, methamphetamine, methylenedioxy methanphetamine, ketamine and cocaine) within 1 year before the first injection;
  13. Medication history of any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicines, etc.) or health care products within 14 days before the first injection;
  14. Vaccinated with within 4 weeks before the first injection or planning to receive live vaccines within 4 weeks after the last dose. Live vaccines include but not limited to: measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin, typhoid fever, COVID-19 live vaccines, etc.;
  15. Any surgical, medical or laboratory pathophysiological conditions that may interfere with the safety, distribution, metabolism or excretion of the drug at the discretion of the investigator;
  16. Unable to communicate or cooperate with medical staff due to neurological, mental disorders or language/ verbal communication issues;
  17. Other situations not suitable for participation in the study as judged by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Part 1: Group 1

    10ug Intrascar injection

    Drug: STP705

  • Experimental
    Part 1: Group 2

    20ug Intrascar injection

    Drug: STP705

  • Experimental
    Part 1: Group 3

    40ug Intrascar injection

    Drug: STP705

  • Experimental
    Part 1: Group 4

    60ug Intrascar injection

    Drug: STP705

  • Experimental
    Part 1: Group 5

    80ug Intrascar injection

    Drug: STP705

  • Experimental
    Part 1: Group 6

    100ug Intrascar injection

    Drug: STP705

Interventions

  • DrugSTP705

    STP705 Powder for Injection composed of siRNA-TGF-B1 and siRNA-COX-2 packged in a proprietary polymer nanoparticle formulation for delivery.

06

What researchers measure

Primary outcomes

  1. Concentration of siRNA-TGF-B1 and siRNA-COX-2 in serum

    siRNA-TGF-B1 and siRNA-COX-2 and HKP will be calculated

    Time frame: 7 weeks

Secondary outcomes

  1. Change of the scar from baseline using Observer Scar Assessment Scale

    The scale will be used to record: vascularity, pigmentation, thickness, releif, pliability, surface area of the scar where 1= Normal skin and 10 = the worst case.

    Time frame: 7 weeks

  2. Change of the scar from baseline using Patient scale

    The scale will be used to record: pain, itching, color, hardness, thickness, and relief where 1= No, not different from normal and 10 = Yes, very different from normal.

    Time frame: 7 weeks

07

Study locations

1 site
  • The 9th Hospital of Shanghai
    Shanghai, Shanghai Municipality 200000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 19, 2022
StartActual
Dec 7, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05196373
Lead sponsor
Sirnaomics
Responsible party
Sponsor
First posted
Jan 19, 2022
Start date
Dec 7, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Jul 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion